Literature DB >> 23140456

In vivo delivery of morpholino oligos by cell-penetrating peptides.

Hong M Moulton1.   

Abstract

Morpholino oligos (Morpholinos) are widely used tools for knocking down gene expression and are currently in a clinical trial for treatment of Duchene muscular dystrophy. A Morpholino analog has been in a clinical trial as a potential anti-bioterrorism agent for inhibiting replication of deadly Marburg viral infection. The cellular uptake of Morpholinos can been greatly increased by conjugation with cell-penetrating peptides (CPP). The use of the CPP-Morpholino conjugates (PPMOs) in vivo has been broadly demonstrated in viral, bacterial, genetic and other diseases. The following aspects of PPMOs will be discussed in this paper including chemistry, stability, antisense specificity, mechanism of cellular uptake, in vivo efficacy, tissue distribution, pharmacokinetics, toxicity and the human clinical trials. PPMOs are powerful research tools for studying gene function in animals and their properties are being improved as potential human therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23140456     DOI: 10.2174/1381612811319160010

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  13 in total

Review 1.  Morpholino-driven gene editing: A new horizon for disease treatment and prevention.

Authors:  E Subbotina; S R K Koganti; D M Hodgson-Zingman; L V Zingman
Journal:  Clin Pharmacol Ther       Date:  2015-11-10       Impact factor: 6.875

Review 2.  Membrane-active peptides from marine organisms--antimicrobials, cell-penetrating peptides and peptide toxins: applications and prospects.

Authors:  Nisha Ponnappan; Deepthi Poornima Budagavi; Bhoopesh Kumar Yadav; Archana Chugh
Journal:  Probiotics Antimicrob Proteins       Date:  2015-03       Impact factor: 4.609

3.  Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers.

Authors:  Yuchen Nan; Zexu Ma; Harilakshmi Kannan; David A Stein; Patrick I Iversen; Xiang-Jin Meng; Yan-Jin Zhang
Journal:  Antiviral Res       Date:  2015-06-15       Impact factor: 5.970

4.  Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment.

Authors:  Jose Portilla-Arias; Rameshwar Patil; Hui Ding; Julia Y Ljubimova; Satoshi Inoue; Janet L Markman; Arthur Rekechenetskiy; Bindu Konda; Pallavi R Gangalum; Alexandra Chesnokova; Alexander V Ljubimov; Keith L Black; Eggehard Holler
Journal:  J Drug Target       Date:  2013-09-16       Impact factor: 5.121

Review 5.  Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells.

Authors:  Carmen Bertoni
Journal:  Front Physiol       Date:  2014-04-21       Impact factor: 4.566

6.  CX3CR1 Is a Receptor for Human Respiratory Syncytial Virus in Cotton Rats.

Authors:  Gia Green; Sara M Johnson; Heather Costello; Kelsey Brakel; Olivia Harder; Antonius G Oomens; Mark E Peeples; Hong M Moulton; Stefan Niewiesk
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

7.  Reciprocal regulation of A-to-I RNA editing and the vertebrate nervous system.

Authors:  Andrew C Penn; Ales Balik; Ingo H Greger
Journal:  Front Neurosci       Date:  2013-04-18       Impact factor: 4.677

Review 8.  Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain.

Authors:  Brandon J Walters; Amber B Azam; Colleen J Gillon; Sheena A Josselyn; Iva B Zovkic
Journal:  Front Genet       Date:  2016-01-12       Impact factor: 4.599

Review 9.  Molecular Biology and Infection of Hepatitis E Virus.

Authors:  Yuchen Nan; Yan-Jin Zhang
Journal:  Front Microbiol       Date:  2016-09-07       Impact factor: 5.640

10.  PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis.

Authors:  Cristiano Sacchetti; Yunpeng Bai; Stephanie M Stanford; Paola Di Benedetto; Paola Cipriani; Eugenio Santelli; Sonsoles Piera-Velazquez; Vladimir Chernitskiy; William B Kiosses; Arnold Ceponis; Klaus H Kaestner; Francesco Boin; Sergio A Jimenez; Roberto Giacomelli; Zhong-Yin Zhang; Nunzio Bottini
Journal:  Nat Commun       Date:  2017-10-20       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.